Clinical-trial participants saw their knee pain abate and could engage better with activities that got them up and going.
Popular GLP-1 drugs are already known to have many benefits, but scientists continue to explore what else they — and their ...
A University of Alberta pharmacology researcher has discovered that a new experimental anti-obesity drug improves diastolic ...
Anti-obesity drugs like Ozempic can offer troops fast weight loss, and their use has grown across the ranks in recent years, ...
Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing ...
The UK’s AstraZeneca, which is working on an oral GLP-1, also views the drugs as part of a combination strategy. In other ...
The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...
The Motley Fool on MSN3h
3 Potential Catalysts That Could Lift Pfizer Stock Before 2025Pfizer's newest anti-obesity program may disclose some of its early data soon ... That makes Pfizer's program fairly unusual ...
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...
A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than ...
The updated AAP clinical guidelines on obesity treatment recommend offering the full spectrum of care upon initial obesity ...
Obesity treatment shifts from surgery to drugs as bariatric procedures decline by 25.6% and GLP-1 receptor agonist use jumps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback